Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study Participants

Inclusion Criteria:

• Female participants aged 18 to 65 years (inclusive) at the time of signing informed consent.
• Participants must be overtly healthy as determined by the investigator based on medical history, physical examination, vital signs, ECG, and clinical laboratory assessments.
• Body weight ≥50 kg and body mass index (BMI) between 18.0 and 32.0 kg/m² (inclusive) at screening.
• Women of childbearing potential must agree to use a highly effective method of contraception during the study and until 14 days after last administration of study intervention.
• Signed informed consent obtained prior to any study-specific procedures.

Exclusion Criteria:

• Diseases or conditions that may affect absorption, distribution, metabolism, elimination, or effects of the study intervention(s).
• Known or suspected hypersensitivity to the study intervention(s) or their excipients.
• Severe allergies or clinically significant hypersensitivity reactions (e.g. allergic asthma, urticaria, or steroid-requiring allergies).
• Febrile illness within 2 weeks prior to first administration of study intervention.
• History of clinically relevant seizures or endometrial tumors.
• Use of moderate or strong CYP3A4 inhibitors or inducers within 4 weeks prior to first study intervention.
• Participation in another clinical study within 30 days prior to first study intervention or concurrent participation in another trial.
• Clinically relevant abnormal laboratory findings at screening, including elevated liver enzymes or positive virology tests.
• Positive pregnancy test at screening or prior to dosing, or breastfeeding. Positive drug abuse or alcohol test at screening.
• Smoking more than 10 cigarettes per day within 3 months prior to screening.
• Special diets incompatible with study requirements or inability to comply with study procedures.